中文
Our Focus



Boyle, JG, et al., Clinical Science (2018) 132 1699–1709


图片1.png



Publications


Title
VenueTypeDate
ASC30, an Oral GLP-1R Biased Small Molecule Agonist Demonstrated Superior Weigh Loss in Participants with Obesity: A 28-Day Multiple Ascending Dose Study

The 61st European Association 

for the Study of Diabetes 

(EASD 2025) 

Short Oral 

Presentation

9/2025
ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate For Obesity, Demonstrated Significant Weight Loss And Preserved Muscle In DIO Mice

The 32nd European Congress 

On Obesity 

(ECO 2025)

Oral5/2025
ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose Study

The 32nd European Congress 

On Obesity 

(ECO 2025)

Guided 

poster

5/2025
ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study

 The American Diabetes 

Association's 85th 

Scientific Sessions 

(ADA 2025)

Poster6/2025
ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

The American Diabetes 

Association's 85th 

Scientific Sessions 

(ADA 2025)

Poster6/2025


  • © 2018 Ascletis Pharma Inc.

contact

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号 浙ICP备11050387号-1